BrainCool AB (publ) has received a new order of IQool™, in the state of Utah, USA

Yet another hospital have placed an order of two IQool™ Systems with a corresponding order value of approximately USD 60.000, without a need for a test and evaluation.

CEO Martin Waleij comments:

The order is yet another sign of the acceptance of the product, based on the evidence and performance from other US and European sites.

We expect to implement the product in Utah and other states in the Western part of the US throughout 2020.

We remain confident that evaluations implemented in 2019 will result in business throughout 2020, and that the output of these evaluations will form av base for further growth.

This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on February 13, 2020.

For more information

Martin Waleij - CEO                                                               
+46 - 733 -93 70 76                                                                                          
E-mail: martin.waleij@braincool.se                       

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.